Drugs that inactivate monoamine oxidase would be expected to
A) reduce dopamine levels within the blood.
B) elevate acetylcholine levels within the muscles.
C) reduce serotonin levels in the synaptic cleft.
D) cause the release of serotonin into the synaptic cleft.
E) increase dopamine levels within neurons.
Question 2
Deprenyl may delay the progression of symptoms in Parkinson's disease because this drug
A) facilitates monoamine oxidase-A.
B) reduces dopamine activity in the synapse.
C) inhibits monoamine oxidase-B.
D) acts on dopamine autoreceptors.
E) is a potent D1/D2 agonist.
